Product logins

Find logins to all Clarivate products below.


Chronic Obstructive Pulmonary Disease – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of COPD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total COPD prevalent cases for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s COPD forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of COPD and the number of new diagnoses of COPD?
  • Of all people diagnosed with COPD, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of COPD over the forecast period?

In addition to the total COPD prevalent cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following COPD subpopulations:

  • Total GOLD-defined COPD prevalent cases
  • Diagnosed spirometric-negative COPD prevalent cases
  • Total GOLD defined prevalent cases by severity
  • Diagnosed COPD prevalent cases
  • Diagnosed prevalent cases by severity
  • Asthma-COPD overlap
  • AECOPD events
  • Eosinophilic COPD
  • Drug treated population

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Sarcoidosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Sarcoidosis (US)
Sarcoidosis is a multisystem inflammatory disorder marked by granuloma formation, most often affecting the lungs, lymph nodes, skin, eyes, and heart. Corticosteroids such as prednisone are the…
Report
Asthma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…
Report
Biosimilars – Forecast – Respiratory
In 2024, sales of branded biologics for respiratory indications totaled $7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2024-2034 forecast…
Report
Cystic Fibrosis – Unmet Need – Unmet Need – Cystic Fibrosis (US EU)
Cystic fibrosis (CF) is a genetic disease associated with more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations cause aberrant…